MPs Caution British Agreements with the Trump Administration are 'Built on Sand'.

Elected officials have issued warnings that the United Kingdom's series of deals with the US administration are "built on sand." This comes after revelations that a recently announced deal on pharmaceutical tariffs, which commits to zero tariffs in exchange for the NHS increasing its costs, lacks any underlying contract beyond vague headline terms published in government press releases.

Lacking Legal Footing

The deal on drug tariffs, hailed as a "generational" achievement, remains an "agreement in principle" without detailed provisions. Critics have noted that the public statements from the UK and US governments present the deal in divergent terms. The British version emphasizes securing "zero per cent tariffs" as a unique achievement, while the American announcement highlights the commitment for the NHS to pay higher prices for new medications.

"There is a serious risk that the UK government has agreed to terms to increase medicine costs in return for little more than a pledge from President Trump," commented David Henig, a trade expert. "History shows he has a record of not keeping promises."

Broader Instability and a Paused Tech Deal

Anxieties have been heightened by Washington's move to suspend the high-value digital accord, which was previously heralded as "a huge leap forward" in the bilateral relationship. The US cited a lack of progress from the UK on addressing wider trade issues as the reason for the pause.

Additionally, concessions secured for British farmers as part of an earlier tariff deal have yet to be formally ratified by the US, despite a fast-approaching January deadline. "Our understanding is that the US has not yet signed off the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Anxiety Behind Closed Doors

Behind the scenes, ministers have voiced worries that the government's US-UK accords are lacking substance. One minister was quoted as stating the series of agreements as "built on sand," while another framed the situation as the "new normal" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, a senior MP on the health committee, argued: "Perhaps most shocking than Trump's temper tantrums is the UK government's optimistic assumption that his administration is a good faith actor. The NHS is of vital importance."

A Mixed Picture of Success and Setback

Government figures have downplayed the risk of the US withdrawing from the pharmaceuticals deal. One source suggested the US pharmaceutical industry itself had been lobbying for the agreement, seeking certainty on imports and pricing, making it of tangible value than the paused tech deal.

Officials admit that instability is part and parcel of dealing with the Trump administration. However, they contend that the UK has secured concrete outcomes for businesses, such as reduced duties on automobiles compared to other nations. "Securing 25% steel tariffs, which is lower than the rate for the rest of the world, is not flimsy," one official said.

Nevertheless, delays have arisen in enacting the May tariff agreement. Promised quotas on beef exports have not materialized, and the pledge to "eliminate duties on UK metals" has remains unmet, with tariffs staying at 25%.

As negotiations continue, the two sides have scheduled to restart talks on the paused tech prosperity deal in January, following what were described as "productive" meetings between UK and US officials in Washington.